Gilead Earnings Bring Mixed Results
Gilead Corporation (NASDAQ: GILD) has joined other biotech giants in releasing its earnings for the third quarter of 2017. The company’s market cap was last seen at $101 billion before earnings, and that was…
Gilead Corporation (NASDAQ: GILD) has joined other biotech giants in releasing its earnings for the third quarter of 2017. The company’s market cap was last seen at $101 billion before earnings, and that was…
National Vision Holdings entered the market with a bang Thursday morning. The company priced its shares above the expected range.
Despite mixed results, with earnings were fairly positive for the quarter, this was not enough to outweigh poor guidance. Shares sank to a new 52-week low.
The October 13 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
The October 13 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
These are four top companies for more aggressive investors looking for health care exposure to consider.
The tale of two biotechs appears to be playing out between Aimmune Therapeutics and DBV Technologies, not just for the companies but between analysts as well.
At least eight large biotech and pharma outfits are scheduled to report their latest earnings and revenues this coming week.
In 2015, 9 million people died prematurely as a result of pollution. That's 16% of all human deaths worldwide for the year. A new study looks at what can be done.
Now there is a new FDA approval Gilead's CAR T lymphoma treatment named Yescarta that has created at least some buzz for Gilead.
These four top companies all have data that could move the shares the rest of this year and into 2018. All have been around for years and will remain sector leaders for years to…
With Eli Lilly making a huge headline investment in a cancer vaccine, 24/7 Wall St. wanted to look under the hood to see what this deal really entails.
24/7 Wall St. tracks key analyst calls in the stocks that move the markets and which are important to investors. It has been almost amazing to see just how many price targets have been…
Spectrum Pharmaceuticals saw its shares make a solid gain early on Wednesday after the firm announced interim data from its mid-stage trial for the treatment of non-small cell lung cancer.
UnitedHealth Group beat EPS and revenue estimates for the third quarter despite a sharp hit related to withdrawing from the ACA program.